456 Studies Now Enrolling
A Randomized, Double-Blind, Placebo and Active-Control, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users with Moderate-to-Severe Opioid Use Disorder
Assessing the Abuse Potential of Oxymorphone in Opioid Use Disorder Patients
| Sponsor: | Food and Drug Administration |
| Enrolling: | Male and Female Patients |
| Study Length: | 8 Weeks |
| Clinic Visits: | 45 |
| IRB Number: | 7565 |
| U.S. Govt. ID: | NCT03205423 |
| Contact: | Vincent Woolfolk, MA: 646-774-6243 / surc@columbia.edu |
Additional Study Information:
This 8-week inpatient study seeks to recruit healthy male and female patients who are currently using heroin or non-medically using opioid analgesics. Following screening, participants are admitted onto the inpatient unit where they complete testing sessions throughout the inpatient stay. Participants are compensated for each screening visit and for each inpatient day if they enroll in the trial. Total payments will be approximately $6720.
This study is closed
